<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076635</url>
  </required_header>
  <id_info>
    <org_study_id>GIPF-006</org_study_id>
    <nct_id>NCT00076635</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF</brief_title>
  <official_title>An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InterMune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InterMune</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label therapy will be administered to up to 220 patients, following completion of either
      InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of
      subcutaneous Interferon gamma-1b. The study duration will be 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label therapy will be administered subcutaneously. Patients enrolled will continue to
      receive Interferon gamma-1b therapy three times per week and will be evaluated at 6-week
      intervals. Patients not taking Interferon gamma-1b at enrollment will re-initiate therapy
      with subcutaneous Interferon gamma-1b under a dose-escalation scheme, reaching full dose
      after 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    program discontinued based on GIPF-007 results
  </why_stopped>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All adverse events up to the end of study</measure>
    <time_frame>3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival status at end of study</measure>
    <time_frame>3.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum antibodies to Interferon gamma-1b after the last injection.</measure>
    <time_frame>3.5 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">91</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Lung Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon gamma-1b</intervention_name>
    <description>200 mcg, SQ, 3x per week</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Enrollment in Protocol GIPF 002 Part B or GIPF-004

          -  Completion of the End of Treatment Visit in Protocol GIPF-002 Part B or the Study
             Completion Visit in GIPF-004

          -  Able to understand and sign a written informed consent form and comply with the
             requirements of the study

        Exclusion criteria:

          -  pregnancy or lactation

          -  lack of adherence to either GIPF-002 or GIPF-004 study protocols and treatment
             regimens

          -  if Principal Investigator deems patient is unsuitable for study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>InterMune, Inc. 888-486-6411</last_name>
    <affiliation>Medical Information</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intermune Inc</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2004</study_first_submitted>
  <study_first_submitted_qc>January 29, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2004</study_first_posted>
  <last_update_submitted>November 2, 2007</last_update_submitted>
  <last_update_submitted_qc>November 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2007</last_update_posted>
  <keyword>Idiopathic</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>IPF</keyword>
  <keyword>Lung</keyword>
  <keyword>Actimmune</keyword>
  <keyword>Interferon</keyword>
  <keyword>Gamma</keyword>
  <keyword>InterMune</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

